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Xiaorong Zhang†, Yantao Wu*†, Yezhen Huang and Xiufan Liu*Abstract
Background: In many countries, the predominant field isolates of infectious bronchitis virus (IBV) have been
classified as QX-like strains since 1996. However, no commercial vaccines that are specific for this type of IBV are
currently available. Therefore, there is an urgent need to develop novel vaccines that prevent QX-like IBV infection.
Results: A recombinant Marek’s disease virus (MDV), rMDV-S1, that expresses the S1 subunit of the spike (S) protein
from the QX-like infectious bronchitis virus (IBV) was constructed by inserting the IBV S1 gene into the genome of
the CVI988/Rispens strain of MDV. Specific pathogen-free (SPF) chickens that were vaccinated with rMDV-S1 were
protected when challenged with the QX-like IBV. They were observed to have mild clinical signs of disease, a short
virus-shedding period and low mortality. Additionally, the rMDV-S1 conferred full protection to chickens against
virulent MDV, as did the CVI988/Rispens strain.
Conclusions: Our results demonstrate that rMDV-S1 is an effective and promising recombinant vaccine for the
prevention of QX-like IBV infection.
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Infectious bronchitis (IB) is an acute, contagious disease of
both layer and broiler chickens. This disease is caused by in-
fectious bronchitis virus (IBV) and has respiratory signs. In
hens infected with IBV, decreased egg production and qual-
ity are often observed. Some IBV strains are nephropatho-
genic, and infection with these strains can result in
interstitial nephritis and mortality [1]. IBV encodes four
major structural proteins: the spike (S) protein, the nucleo-
capsid (N) protein, the membrane (M) protein, and the
envelope (E) protein. The S protein of IBV is initially trans-
lated into a precursor glycoprotein that is cleaved post-
translationally to form two subunits, S1 and S2 [2]. Most of
the virus-neutralizing antibodies target the S1 protein [3].
Currently, both modified live and inactivated vaccines are
commercially available [1]. Despite the intensive vaccination* Correspondence: ytwu@yzu.edu.cn; xfliu@yzu.edu.cn
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reproduction in any medium, provided the orefforts, outbreaks of IBV frequently occur due to the persist-
ence of different IBV serotypes. These serotypes arise from
point mutations, insertions, deletions, and RNA recombin-
ation [3]. Multiple distinct genetic groups of IBV have been
reported, but since 1996, the predominant field isolates in
China have been classified as QX-like (LX4-type) [4-8].
QX-like IBVs are circulating in almost all of the countries in
Europe, and these variants are frequently associated with
cases of nephritis and false layer syndrome in chickens
[9-14]. Clearly, QX-like IBVs are a serious threat to the
poultry industry. However, no vaccines against QX-like IBVs
are commercially available. Therefore, there is an urgent
need to develop vaccines that can prevent QX-like IBV
infection.
Marek’s disease (MD) is a transmissible, malignant T-cell
lymphoma in chickens caused by Marek’s disease virus
(MDV) [15]. MDV strains are classified into the following
three serotypes: Gallid herpesvirus 2 (MDV serotype 1),
Gallid herpesvirus 3 (MDV serotype 2), and Meleagrid her-
pesvirus 1 (MDV serotype 3/herpesvirus of turkeys) [16].Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Identification of the transfer vector by restriction
enzyme digestion analysis. M: DNA Marker; Lane 1: pUP-S1-DOWN
digested with Avr II and Not I; Lane 2: pUP-LTR-EGFP-S1-DOWN
digested with Not I; Lane 3: pUP-LTR-EGFP-S1-DOWN digested with
Hind III.
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serotype 1, and they range from highly virulent to weakly
virulent strains. These strains, such as CVI988/Rispens,
may be attenuated by extensive serial passage in tissue cul-
ture, with loss of pathogenic properties but retention of
immunogenicity. The CVI988/Rispens strain provides
good protection against challenge even with the newly dis-
covered highly virulent pathotype of MDV [1].
MDV has several ideal characteristics that make it useful
as a vector for recombinant vaccine. MDV infection results
in a persistent infection, and because it is transmitted cell
to cell, the virus is not susceptible to maternal antibodies.
Furthermore, the virus has a large genome with several
regions that are not essential for viral replication, which
are suitable for the insertion of foreign genes [17]. In the
present study, a recombinant MDV (rMDV) expressing
the S1 protein from QX-like IBV (rMDV-S1) was con-
structed, and the protective efficacy of the virus as a vac-
cine against both IBV and MDV in SPF chickens was
investigated.
Results
Construction of the transfer vector
To construct the recombinant MDV, a transfer vector
called pUP-LTR-EGFP-S1-DOWN was constructed by
inserting the IBV S1 gene, the LTR promoter from reti-
culoendotheliosis virus (REV) and an EGFP expression
cassette into the pUP/DOWN plasmid. The construction
of the transfer vector was verified by restriction enzyme
digestion analysis (Figure 1) and DNA sequencing.
Construction and characterization of the recombinant
viruses
First, we analyzed the recombinant rMDV-EGFP-S1 for
the expression of the EGFP protein by fluorescence mi-
croscopy. When all the plaques were visibly fluorescent,
the EGFP gene between the two loxP sites was removed by
Cre-mediated recombination. The recombinant viruses,
rMDV-EGFP-S1 and rMDV-S1, were verified by a series of
PCR reactions. The results indicated that recombination
occurred at the expected locus in the CVI988/Rispens gen-
ome, and all inserted elements were arranged as intended
(Figure 2).
To confirm the expression of the S1 protein of rMDV,
an RT-PCR assay was used to detect S1 gene mRNA
transcription in rMDV-S1-infected chicken embryo
fibroblasts (CEFs) using the S1-F and S1-R primers. An
expected 1.7-kb PCR product could be amplified from
mRNA isolated from the rMDV-S1-infected CEFs but
not from CVI988/Rispens-infected CEFs (Figure 3). CEFs
infected with the rMDV-S1 were stained with chicken
anti-IBV serum. Plaques from the rMDV-S1 were stained
by the chicken anti-IBV serum, whereas plaques from
the CVI988/Rispens virus were not (Figure 4).The rMDV-S1 virus was genetically stable after 30
sequential passages in CEFs.
Induction of the IBV antibody response
Figure 5 indicates the change in the levels of IBV-specific
antibodies following the inoculation of SPF chickens with
rMDV-S1, CVI988/Rispens, or phosphate buffered saline
(PBS) that were subsequently challenged with IBV. No
specific, anti-IBV antibodies were detected in chickens that
were inoculated with CVI988/Rispens or PBS. The rMDV-
S1 vaccinated chickens were observed to have a low-level
antibody response until 4 weeks post-vaccination, but after
IBV challenge, the antibody level increased more rapidly
compared with the control group. These results indicated
that the rMDV-S1 virus could induce an IBV-specific im-
mune response in vaccinated chickens.
Protection against IBV challenge
Following challenge with the IBV, CK/CH/JS/06II strain,
70% (14/20) of the chickens in the rMDV-S1-vaccinated
Figure 2 Verification of the structure of the rMDVs by a series of PCR reactions. The S1 gene could be detected from both rMDV-EGFP-S1
(lane 2) and rMDV-S1 (lane 3) with primers S1-F and S1-R. The transfer vector pUP-LTR-EGFP-S1-DOWN was used as positive control (lane 1), and
CVI988/Rispens DNA was used as a negative control (lane 4). The correct orientation of the inserted genes was further confirmed with the primers
PLTR-F and S1-R (lanes 6 and 7). The transfer vector pUP-LTR-EGFP-S1-DOWN was used as a positive control (lane 5), and CVI988/Rispens DNA was
used as a negative control (lane 8). The incorporation of the foreign gene in the correct site of rMDV-S1 genome was also verified with the
following three primer pairs: Geno-F and Geno-R (lane 9), Geno-F and PLTR-R (lane 11), and S1-F2 and Geno-R (lane 12). CVI988/Rispens DNA was
used as a negative control (lane 10).
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ens survived. In contrast, all of the chickens in the con-
trol group and in the CVI988/Rispens-vaccinated group
developed serious clinical symptoms and were observed
to have a higher mortality after challenge with IBV, CK/
CH/JS/06II strain (Table 1). All deaths occurred within 3
to 5 days after challenge. A chi-squared (χ2) test to com-
pare the morbidity and mortality between each treatment
group indicated that there was a significant difference
(p< 0.05) between the rMDV-S1-vaccinated group and
the PBS mock-vaccinated group.
From days 2 to 12 after challenge, tracheal swabs were
collected for virus isolation from 10 randomly selected
chickens from each group. The results indicated that the
virus could be recovered from the rMDV-S1-vaccinated
group from days 4 to 8 and from the two control groups
from days 4 to 10. The χ2 test indicated that at specific
time points, there was a significant difference between the
rMDV-S1-vaccinated group and the PBS mock-vaccinated
group (p< 0.05) in the number of tracheal swabs thattested positive for the virus (Table 2). The virus detec-
tion rate from the kidneys of the chickens in the rMDV-
S1-vaccinated group was lower compared with the con-
trol groups. There was a highly significant difference
(p< 0.01) in the number of kidneys that tested positive
for the virus between the rMDV-S1-vaccinated and the
PBS mock-vaccinated groups (Table 2). Together, these
data indicate that in the rMDV-S1-immunized group,
the virus-shedding period was shorter than that of the
control groups.
Table 3 indicates that after challenge, the rate of increase
in the bodyweight of chickens in the CVI988/Rispens-
vaccinated and PBS mock-vaccinated groups was significantly
lower than in the rMDV-S1-vaccinated (p< 0.01) group.
Necropsy of the deceased chickens revealed the typical
pathology of IB. The disease was restricted to the upper
respiratory tract and the kidneys of infected chickens
and characterized by the presence of mucus in the upper
respiratory tract as well as gray and mottled kidneys. On
day 14 post-challenge, microscopic kidney lesions were
Figure 3 RT-PCR verification of S1 gene expression in rMDV
S1-infected CEFs. M: DNA Marker. PCR template used
independently in reactions 1 ~ 5: pUP-LTR-EGFP-S1-DOWN (positive
control); cDNA reverse-transcribed with RNA isolated from
rMDV-S1-infected CEFs; RNA isolated from rMDV-S1-infected CEFs; cDNA
reverse-transcribed from RNA isolated from CVI988/Rispens-infected CEFs;
RNA isolated from CVI988/Rispens-infected CEFs.
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group and the CVI988/Rispens-immunized group, the
lesions were characterized by massive infiltration of
round cells. In the rMDV-S1-immunized group, more
moderate lesions were observed compared with the con-
trol groups (Figure 6).Protection against MDV challenge
To determine the protective efficacy of rMDV-S1 vaccin-
ation against the virulent RB1B strain of MDV, chickens
were vaccinated and then challenged with RB1B MDV
7 days after vaccination and examined for signs of MD
and tumor development for 6 weeks. The chickens vacci-
nated with rMDV-S1 and those vaccinated with CVI988/
Rispens did not show any clinical signs of MD and had
no gross or histopathological tumors. These data indicate
that rMDV-S1 vaccination could confer protection
against MDV. 90% (18/20) of the chickens in the unvac-
cinated control group died of MD, and the remaining 2
chickens had histopathological MD lesions present at the
time of necropsy (Table 4).Discussion
Antigenic variation among IBV strains is common [3,18-
28]. Due to the regular emergence of antigenic variants, the
occurrence of disease and the use of vaccines will vary by
geographical region. According to phylogenetic analysis by
Han et al. [5], most of the recently described IBV isolates
were from 9 distinct genetic groups, and the predominant
group was the QX-like strain [6,29]. In China, the com-
monly used IBV vaccine strains, such as H120, H52 and
M41, are all Mass-type vaccines, and the S1 gene sequence
similarity is low compared with the currently circulating
IBV strains [19]. This result could explain why the increas-
ing number of vaccination failures. Thus, developing novel
vaccines against QX-like IBVs is necessary [5,19,23].
The construction of a recombinant virus vector-based
vaccine is a good option to develop IBV vaccines that are
specific to new IBV serotypes. Fowlpox viruses that express
the IBV S1 gene have been reported previously [30-32],
and all of these vaccines have been described to confer
protection against viral challenge with homotypic IBV
strains and some heterotypic IBV strains in SPF chickens.
However, the protective efficacy that is conferred by
recombinant fowlpox viruses could be diminished in com-
mercial chickens due to the presence of maternal anti-
bodies against fowlpox virus [33,34]. In fact, fowlpox
vaccines are widely used in commercial chickens, which
hinder the application of recombinant vaccines that are
based on fowlpox virus vectors. Compared with other viral
vectors, the CVI988/Rispens has several unique advantages.
The CVI988/Rispens is the most effective MD vaccine
obtained thus far [35]. Additionally, the CVI988/Rispens
can persistently infect chickens, which results in the con-
tinuous expression of inserted, heterologous antigens [17].
Finally, the CVI988/Rispens can be used to inoculate one-
day-old chickens to establish an early immunity.
Although the rMDV-S1 vaccinated group induced a low
level antibody response until 4 weeks post-vaccination, but
the level of antibody increased more rapidly compared to
the control groups following IBV challenge. Additionally,
chickens vaccinated with rMDV-S1 were observed to have
a shorter virus-shedding period and a greater increase in
bodyweight. These results suggested that rMDV-S1
immunization could induce an efficient primary immune
response that was specific to the expressed S1 protein.
When the chickens were challenged with IBV, the primed
B cells could rapidly differentiate into plasma cells, thus
permitting the production of higher titers of IBV-specific
circulating antibody within a shorter period of time. This
finding is important for the establishment of an early-stage
active immune response against IBV infection.
Conclusions
We constructed a recombinant MDV, called rMDV-S1, that
expressed the S1 protein of a QX-like IBV. Vaccination
a b
dc
Figure 4 Detection of S1 protein expression by IFA. Plaques of rMDV-S1 were immunologically stained with an IBV-specific antibody, whereas
plaques of CVI988/Rispens were not.
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against both IBV and MDV challenge. Taken together,
rMDV-S1 is a promising vaccine candidate for the control
of infection by QX-like IBVs: the major IBV genotype cur-
rently circulating in many countries.Materials and Methods
Viruses, SPF chicken embryos and chickens
The CVI988/Rispens strain of MDV was used as the vec-
tor for the construction of the recombinant virus, and
the virulent RB1B strain of MDV was used as the chal-
lenge virus. MDVs were propagated in secondary CEFsFigure 5 Antibody responses to IBV after vaccination and
challenge. The vaccination time-point (1-day-old) was recorded as 0
w. Chickens were challenged at 4 w post-vaccination.in Medium 199 supplemented with 3% newborn calf
serum (Thermo Fisher Scientific).
The QX-like IBV strain CK/CH/JS/06II was used for
S1 gene [GenBank: EU031526] amplification and as the
challenge virus. The challenge dose was determined in a
previous experiment in SPF chickens. This dose (2 × 103.5
EID50 per chicken) could induce clinical signs, including
death, beginning on day 2 post-challenge.
SPF chicken embryos were purchased from Merial-Vital
Laboratory Animal Technology Co., Ltd. (Beijing, China).
SPF chickens were hatched from SPF embryos and reared
in negative-pressure isolators. Feed and water were available
ad libitum. This study was conducted in strict accordance
with the recommendations given in the Guide for the Care
and Use of Laboratory Animals of the National Research
Council. The animal care and use committee of Yangzhou
University approved all experiments and procedures con-
ducted on the animals (approval ID: SYXK (Su) 2007-0005).Table 1 Morbidity and mortality of vaccinated chickens
after challenge with the IBV CK/CH/JS/06II strain
Groups Morbidity Mortality
rMDV-S1 6/20 a 1/20 a
CVI988/Rispens 20/20 b 6/20 b
PBS 20/20 b 6/20 b
Note: The criteria for morbidity were as follows: (1) wheezing or dyspnea, (2)
swinging of the head, and (3) feathers erected and dullness. The presence of
any of these criteria can be used to evaluate morbidity. The morbidity and
mortality among the four experimental groups are indicated with different
lowercase letters and differ significantly based on χ2 analysis (p< 0.05).
Table 2 Virus isolation from tracheal swabs or from the
kidneys of vaccinated chickens after challenge with the
IBV CK/CH/JS/06II strain
Groups Isolation of virus★
Days post-virus challenge
2* 4* 6* 8* 10* 12* 14**
rMDV-S1 0/10 a 10/10 a 4/10 a 1/10 a 0/10 a 0/10 a 2/19 a
CVI988/Rispens 0/10 a 10/10 a 10/10 b 6/10 b 3/10 b 0/10 a 14/14 b
PBS 0/10 a 10/10 a 10/10 b 6/10 b 4/10 b 0/10 a 14/14 b
* Virus isolation from trachea swabs.
** Virus isolation from kidney.
★ Virus isolation from the trachea or the kidney from the four experimental
groups, as indicated with different lowercase letters, differed significantly
based on χ2 analysis (p< 0.05).
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The plasmid pUP/DOWN that contained the homologous
sequence to the IRS-US junction region of the CVI988/
Rispens genome [GenBank: DQ530348], the plasmid
pLTR-GFP that contained a loxP-flanked EGFP expression
cassette and a LTR promoter from REV were constructed
previously by Li et al. [36]. The S1 gene from the IBV
strain CK/CH/JS/06II was amplified from genomic RNA
with M-MLV reverse transcriptase and Phusion® High-
Fidelity DNA Polymerase (New England BioLabs) using
primers S1-F (5′-AAAGCGGCCGCGAGATGTTGGG
GAAGTCACTG-3′) and S1-R (5′-ATTCCTAGGTTAG
CCATAACTAACATAAGGGCAACT-3′). These primers
were designed based on the S1 gene sequence of CK/CH/
JS/06II. Artificial Avr II and Not I restriction sites (under-
lined) permitted the direct cloning of a 1641-bp fragment
of the resulting amplicon into the pUP/DOWN vector.
This resulted in the plasmid pUP-S1-DOWN. To produce
the transfer vector pUP-LTR-EGFP-S1-DOWN containing
an EGFP reporter gene, the plasmid pLTR-GFP was
digested with Not I (New England BioLabs), and the LTR-
EGFP expression cassette was cloned into the Not I-
digested, pUP-S1-DOWN plasmid in the same orientation
as the S1 gene (Figure 7a). The insertion of both the S1
gene and LTR-EGFP was verified by Avr II and Not I (New
England BioLabs) digestion. The correct orientation of theTable 3 Bodyweight changes of vaccinated chickens after
challenge with the IBV CK/CH/JS/06II strain
Groups Bodyweight (g)*
1-day-old Pre-challenge Post-challenge
rMDV-S1 49.5 ± 0.8 a
(n = 20)
259.6 ± 10.9 a
(n = 20)




49.4 ± 0.7 a
(n = 20)
256.6 ± 11.4 a
(n = 20)
395.7 ± 48.7 b
(n = 14)
PBS 49.5 ± 1.1 a
(n = 20)
258.8 ± 10.9 a
(n = 20)
391.6 ± 50.9 b
(n = 14)
* Mean ± SE. Bodyweight among the four experimental groups, as indicated
by different lowercase letters, differed significantly based on χ2 analysis
(p< 0.05).insertion was confirmed by Hind III (New England BioLabs)
digestion, as illustrated in Figure 7b. The transfer vector
was further confirmed by gene sequencing (GenScript,
Nanjing, China).
Construction of rMDV
The recombinant virus was produced by calcium
phosphate-mediated transfection of secondary CEFs that
were cultured in a 60-mm dish with 100 ng of the pUP-
LTR-EGFP-S1-DOWN transfer vector and 10 μg of
CVI988/Rispens genomic DNA [37]. The transfected CEFs
were cultured at 37°C in 5% CO2 for 5–7 days until viral
plaques were visible. Viral plaques that expressed EGFP
were identified by fluorescence microscopy (Leica DM
RIB). These plaques were subsequently scraped from the
monolayer using a micropipette containing a small amount
of 0.25% trypsin. The cells were then aspirated, trypsinized
into a single cell suspension, and passaged repeatedly. This
process was repeated until all of the visible plaques were
fluorescent. The resulting intermediate recombinant virus
rMDV-EGFP-S1 was then amplified in CEFs.
Genomic DNA from the rMDV-EGFP-S1 virus was pre-
pared as described above, and the EGFP gene between the
two loxP sites was excised with Cre recombinase (New
England BioLabs), which ensured that the S1 gene was
placed immediately downstream of the LTR promoter.
The genomic DNA from rMDV-EGFP-S1, in which the
EGFP gene had been excised, was used for subsequent
transfection experiments to generate new recombinant
viruses that contained no reporter gene. The resulting
non-fluorescent rMDV, called rMDV-S1, was screened and
purified as described above. The complete process is illu-
strated in Figure 7c.
PCR Identification of rMDV-S1
Primers S1-F and S1-R were used to amplify the inserted
S1 gene from rMDV-S1. To further verify the correct
orientation of the S1 gene, the primer PLTR-F (5′-AT
CGGCATCAAGAGCAGG-3′) was designed according the
sequence of the LTR promoter in combination with the pri-
mer S1-R that would amplify a 2.0-kb DNA fragment that
comprised part of the LTR promoter sequence and the en-
tire S1 gene sequence if the recombinant virus was engi-
neered correctly. To verify whether the recombination
event occurred at the expected location in the genome of
the CVI988/Rispens vector, four other primers, designated
Geno-F (5′-GCGTAGCCAGACCGCACCA-3′), Geno-R
(5′-GCCTGAATAAAGACCGACA-3′), PLTR-R (5′-ATT
GGCTCAGTATGATAGTTC-3′) and S1-F2 (5′-TTGCC
ACGTCAAGGAAGC-3′), were designed. The binding site
for Geno-F was located upstream of the left homologous
arm (153275–153293 nt in the CVI988/Rispens genome),
and Geno-R was located downstream of the right homolo-
gous arm (154958–154976 nt in the CVI988/Rispens
a b
dc
Figure 6 Examination of histological lesions in the kidneys of vaccinated chickens at 14 d post-challenge (H&E staining, Magnification
400×). (a) Healthy control, (b) PBS control, (c) CVI988/Rispens and (d) rMDV-S1. (b) and (c) were observed to have more severe nephritis
compared with (d). The arrows indicate the regions with infiltration of round cells.
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moter and the S1 gene, respectively. A detailed PCR
scheme is illustrated in Figure 7d.
CEFs were harvested, and the total cellular RNA was pre-
pared using TRIzol reagent (Invitrogen) after 48 hours of
infection with either the rMDV-S1 or CVI988/Rispens.
Total RNA was treated with DNase I (New England
BioLabs) to eliminate any genomic DNA contamination
and was then reverse-transcribed using oligo (dT)15 primers
(Takara, Dalian, China). Subsequently, the S1 gene was
amplified with primers S1-F and S1-R as described above. A
positive control reaction using the transfer vector pUP-
LTR-EGFP-S1-DOWN as the amplification template was
performed. Additionally, a reaction with DNase I- treated
total RNA as the amplification template was included in the










rMDV-S1 - 0% (0/20) 0% (0/20) 0% (0/20) 100
CVI988/
Rispens
- 0% (0/20) 0% (0/20) 0% (0/20) 100
control + 90% (18/20) 95% (19/20) 100% (20/20)
Note: One-day-old SPF chickens were vaccinated with either the rMDV-S1 or
CVI988/Rispens virus and challenged 7 days later with the MDV RB1B strain.
Clinical signs and mortality were observed for 6 weeks, and the chickens that
died during challenge and those that were euthanized at the end of the
observation period were necropsied and subjected to gross and
histopathological examination. Chickens with gross tumor lesions were
considered positive for histopathological lesions.Indirect immunofluorescence assay (IFA)
CEFs were grown in a 24-well tissue culture plate and
infected with rMDV-S1 or the CVI988/Rispens (100 PFU/
well) vector. After incubation for 48 h at 37°C, these cells
were fixed for 15 min with methanol-acetone (1:1) and
incubated for 30 min in the presence of a 5 μg/ml dilution
of a chicken anti-IBV polyclonal antibody that was pre-
pared via multiple immunizations of SPF chickens with the
Mass-type IBV antigen (China Institute of Veterinary Drug
Control, Beijing, China) and a 7.5 μg/ml dilution of fluor-
escein-conjugated rabbit anti-chicken IgY (H+L) (Thermo
Fisher Scientific) at 37°C. After each step, the cells were
washed three times for 5 min with PBS. The cells were
overlaid with 90% glycerol containing 25 mg/ml 1,4 diaza-
bicyclo[2.2.2]octane (Sigma-Aldrich). The binding of the
fluorescein-conjugated, secondary antibodies was analyzed
by fluorescent microscopy (Leica DM RIB).Genetic stability of rMDV
The rMDV-S1 was sequentially passaged in CEFs to de-
termine the genetic stability of the virus. As described
above, the genomic DNA from passages 5, 10, 15, 20, 25
and 30 were extracted and used as a template for ampli-
fication of the S1 gene. IFAs were also applied to confirm
the expression of the S1 gene in each passage.
Protective efficacy of rMDV vaccination against IBV
Sixty, one-day-old SPF white Leghorn chickens were
divided into 3 groups with 20 chickens in each group.
The chickens were raised in individual isolators under
Figure 7 Illustration of the construction of rMDV-S1. (a) Construction of the transfer vector. (b) Identification pattern of the transfer vector by
restriction enzyme digestion. (c) Steps for generating rMDV-S1. (d) Primer binding sites mapped to the genome of the rMDVs.
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neously on the back of the neck with 5 × 103 PFU of
rMDV-S1 or CVI988/Rispens. The third group was
mock-injected with PBS. An additional 10 chickens were
raised separately to serve as the healthy controls.
Serum was collected weekly after vaccination until the
chickens were challenged. Pre-vaccination serum was
also collected. Serum samples were assayed in single
dilutions (1:500) using an Infectious Bronchitis Virus
Antibody Test Kit (IDEXX, ME, USA) according to the
manufacturer’s instructions. S/P ratios that were greater
than 0.2 were considered positive.
Four weeks after immunization, chickens from each
group were challenged by the ocular-nasal administra-
tion of 2 × 103.5 EID50 of the IBV CK/CH/JS/06II strain
in 200 μl PBS per chicken. Any clinical disease symp-
toms, including death, beginning on day 2 post-challenge
were recorded. On days 2, 4, 6, 8, 10, and 12 post-chal-
lenge, tracheal swabs were collected and used for virus
isolation from 10 randomly selected chickens from each
group. Dead chickens were necropsied immediately, and
the live chickens from each group were euthanized
14 days post-challenge. The kidney tissues from all
chickens were collected for virus isolation and patho-
logical examination. Each chicken was weighed at 1-day-
old, pre-challenge and at two weeks post-challenge.
The tracheal swabs and 20% tissue suspensions were
freeze-thawed three times and centrifuged at 1000 × g.
After centrifugation, the resulting supernatant was used
to inoculate the allantoic cavity of 10-day-old SPF
chicken embryos. After 96 hours, the allantoic fluid was
collected, and any pathological changes in the embryos
were recorded. The samples were considered positive for
IBV isolation if the embryos appeared to be congestive,
dropsical or hemorrhagic or if they developed urate de-
position [32]. Otherwise, the embryos were inoculated
for three blind passages. Allantoic fluid from the chicken
embryos was collected and analyzed using RT-PCR as
described above.
The collected kidney tissues were fixed in 10% neutral
buffered formalin. The tissues were processed by stand-
ard histological procedures, embedded in paraffin, and
cut into 5-mm sections. All of the sections were stained
with hematoxylin and eosin (H&E).
Protective efficacy of rMDV vaccination against MDV
A total of 60 SPF chickens were used in this experiment.
Twenty, 1-day-old SPF chickens were vaccinated with the
rMDV-S1 or the CVI988/Rispens as described above and
challenged intraperitoneally after 7 days with MDV, RB1B
strain (500 PFU/chick). Twenty unvaccinated SPF chickens
were used as the challenge controls. The chickens were
examined for clinical signs of disease and mortality for
6 weeks after challenge. The chickens that died afterchallenge and those that were sacrificed at the end of the
challenge period were subjected to gross and histopatho-
logical observations for MD lesions in the liver, kidneys,
spleen, nerves, and skin [17]. The protection index (PI)
was calculated by the following formula [38]:
PI %ð Þ ¼ %MD positive in controls−%MD in vaccine group
%MD positives in controls
 100
Statistical analyses
The differences in morbidity, mortality and virus-shedding
period from the tracheal swaps and kidneys between each
group were compared using the χ2 test. The difference in
the increase in body weight (means ± SE) between each
group was analyzed by Student’s t tests. The increase in
bodyweight was analyzed by ANOVA. All statistical
analyses were performed using the SPSS software (version
17.0. SPSS Inc., IL, USA).
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